Dialysis and Renal Care Market: GCC and India outlook 2026–2032

Dialysis is one of the fastest-growing service lines in the GCC and India because of the diabetes and hypertension burden. Published estimates for 2025 range from USD 99.5 bn to USD 126 bn depending on geography and whether services, consumables and equipment are combined; our central estimate is USD 115 bn, growing at about 6% to USD 167 bn by 2032.

The GCC has among the highest ESRD incidence rates globally and is outsourcing dialysis provision through PPPs and private chains (DaVita, Diaverum, Fresenius NephroCare, local groups); India’s dialysis is expanding through PM-NDP public programmes, hospital chains and specialist operators (NephroPlus, Apex Kidney Care, DaVita India). Cost per session is driven by dialysers, bloodlines, dialysate, ESAs and IV iron — all contractable.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 99.5 bn–USD 126 bn; differences are mostly scope.

Included: in-centre and home haemodialysis, peritoneal dialysis, dialysis equipment and consumables, renal pharmaceuticals (ESAs, iron, binders) where reported with services, CKD clinics. Excluded: transplantation (context only).

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Over 850 million people globally had kidney disease in 2025; global dialysis patient population exceeded 4.9 million (IMARC)
• Global kidney-failure treatment population rose from 1.59 mn (1990) to 4.59 mn (2023) (GMI)
• India dialysis penetration below 10% of ESRD patients; China ~132 mn CKD patients with dialysis penetration below 30% of eligible (IMARC)
• US: >540,000 patients on dialysis in 2025; Japan ~3,200 dialysis patients per million population (IMARC)
• Diaverum is Saudi Arabia's largest renal care provider with 40 clinics in 33 cities and 1,300 healthcare professionals; acquired by M42 in 2023 (Arabian Business)
• Over 16% of UAE adults have diabetes, a leading cause of kidney failure (Arabian Business)
• NephroPlus: 275+ centres in 170+ Indian cities serving ~20,000 patients/month; FY24 revenue INR 566 cr (+29%), net profit INR 35 cr, EBITDA margin 19% (IPO Central)
• Fresenius Medical Care treated 293,620 patients in 3,628 clinics (30 Sep 2025); FY2024 revenue EUR 19,336 mn (Fresenius 6-K)
• Fresenius ~20.5% and DaVita ~13.0% global dialysis market share (2025); top-5 ~44.7% (GMI)
• Annual dialysis cost USD 60,000-100,000 per patient in 2025 (developed markets) (IMARC)

GCC

Saudi Arabia contracts dialysis through the clusters and PPPs; UAE providers (SEHA/PureHealth, Mediclinic, NMC, Burjeel, American Hospital, Diaverum, DaVita) serve insurer-covered patients; home dialysis is growing under DoH/DHA licensing.

India

PM-NDP (Pradhan Mantri National Dialysis Programme) under PPP provides free dialysis in district hospitals; NephroPlus is one of the largest networks in Asia; hospital chains run captive units; consumable costs are the competitive battleground.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Hospital leaders: tender dialysers, bloodlines, dialysate and ESAs as a bundle per session with quality KPIs; consider outsourcing where utilisation is below 60%.
• Operators and investors: PPP and insurer-contracted chains in Saudi secondary cities and Indian tier-2 cities; home dialysis.
• Suppliers: cost-per-session models and reliable consumable supply win multi-year contracts.

1. IMARC Group, Dialysis Market Size, Share, Trends and Forecast 2026-2034 — imarcgroup.com
2. Global Market Insights, Dialysis Market Size & Share, 2026-2035 — gminsights.com
3. BioSpace / Nova One Advisor, Dialysis Market Size to Surpass USD 209.75 Billion by 2034 — biospace.com
4. IMARC Group, Middle East Dialysis Market 2026-2034 — imarcgroup.com
5. IMARC Group, Saudi Arabia Hemodialysis Market Expected to Reach USD 1,247.7 Million by 2034 — imarcgroup.com
6. IMARC Group, India Dialysis Market 2025-2033 — imarcgroup.com
7. Arabian Business, M42's Diaverum ventures into UAE — arabianbusiness.com
8. IPO Central, Dialysis centers operator NephroPlus to launch INR 2,127 cr IPO — ipocentral.in
9. SEC / Fresenius Medical Care, Fresenius Medical Care Q3 2025 results (Form 6-K) — sec.gov
10. Deccan Chronicle, Andhra Govt to Add 22 Dialysis Centres under PMNDP — deccanchronicle.com
11. IMARC Group (2026) — USD 125.79 bn (2025) to USD 181.22 bn (2034), CAGR 4.14% (2026-2034); scope: Global dialysis market (services + products); 2030 interpolated value USD 154.08 bn — source
12. Global Market Insights (GMI) (2026) — USD 99.5 bn (2025) to USD 169 bn (2035), CAGR 5.5% (2026-2035); scope: Global dialysis market; 2026 est. USD 104.5 bn; passes USD 110.3 bn in 2027 — source
13. Nova One Advisor / Precedence Research (via BioSpace) (2025-02) — USD 113.75 bn (2024) to USD 209.75 bn (2034), CAGR 6.31% (2025-2034); scope: Global dialysis market; 2025 est. USD 120.93 bn; US USD 35.8 bn (2024) to USD 66.1 bn (2034) — source
14. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
15. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.